International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Focus on Psoriasis: A Report from the 2024 American Academy of Dermatology (AAD) Annual Meeting

The 2024 American Academy of Dermatology (AAD) Annual Meeting was held March 8 – March 12, 2024, in San Diego, California. It’s the largest dermatology meeting in the world, showcasing over 1,000 expert speakers and over 300 sessions. The sessions covered various topics, from medical to cosmetic dermatology, topline data, and clinical pearls. The following report includes 36 summaries of different talks on psoriasis, including the IPC’s Symposium: The Comprehensive Care of Psoriasis. You can download the full report or read on for a quick highlight.

IPC SYMPOSIUM: THE COMPREHENSIVE CARE OF PSORIASIS

  • Dr. Álvaro González-Cantero, IPC Councilor, presented on the Impact of Obesity on Psoriasis. He showed data on the increasing prevalence of obesity, the inflammatory crosstalk in psoriasis comorbidities, and the impact of diet and weight loss strategies, such as GLP-1 agonists.
  • Dr. Maria Angeliki Gkini, 2023 IPC Fellow, shared a Challenging Case: A Patient with Comorbid Solid Organ Malignancy. This patient had severe psoriasis and psoriatic arthritis and was treated with Secukinumab. Dr. Gkini discussed various guidelines and the multidisciplinary approach to care implemented to best support this patient.
  • Dr. Evan Rieder gave a talk about the Identification and Management of Anxiety, Depression, and Stigma in Patients with Psoriasis. Dr. Rieder emphasized the psychological burden of psoriasis and stigmatization that could derive, together with different strategies for early diagnosis and management.
  • Dr. Lucas Galimany, 2022 IPC Fellow, presented a Challenging Case: A Patient with Infection with a longstanding history of severe plaque psoriasis. Dr. Galimany shared the treatment journey of this patient, who was diagnosed with varicella-zoster meningitis.
  • Dr. Johann Gudjonsson, IPC Board Member, discussed Emerging Mechanistic Data Behind Psoriasis and Cardiometabolic Disease, which reviewed the causal link between psoriasis and cardiovascular disease, showing data of a possible bidirectional effect.
  • Dr. Joel Gelfand, IPC Board Member, gave a talk titled How to Identify Cardiovascular Risk in People with Psoriasis, emphasizing the role of dermatologists in cardiovascular screening together with preventative cardiology. He also presented data on the impact of systemic treatments on cardiovascular health.
  • Dr. Arthur Kavanaugh, IPC Councilor, presented the Latest Advances in Screening and Treating Psoriatic Arthritis. He discussed different clinical presentations of joint disease, pathophysiology, and GRAPPA treatment guidelines.
  • Dr. Sonia Chávez-Álvarez, 2023 IPC Fellow, presented A Challenging Case: A Pregnant Patient with acrodermatitis continua of Hallopeau and genital psoriasis initially treated with topicals. Dr. Chávez-Álvarez reviewed approved topical treatments for pregnancy and the risks associated with pregnant psoriatic patients.
  • Dr. Andrew Blauvelt, IPC Board Member, gave a talk titled Hot Psoriasis Topics: Single-cell RNA Sequencing, which showed the latest advances in single-cell analysis that help us broaden our understanding of psoriasis pathogenesis and molecular targeting.
  • Dr. Bruce Strober, IPC Board Member, gave an Update on Psoriasis Therapy, in which he presented data on new drugs for psoriasis patients (e.g., Spesolimab, new TYK2 inhibitor (TAK-279), oral IL-23 receptor antagonist, and Orismilast (new PDE-4 inhibitor)).

PSORIASIS

  • In his talk, Novel Insights in Biomarkers for PsoriasisDr. Andrew Blauvelt, IPC Board Member, discussed the importance of biomarkers in guiding prognosis and therapeutics.
  • Dr. April Armstrong, IPC Councilor, presented Evolving Landscape of Oral Therapies for Psoriasis. Data was shown from emerging studies on new drug development: novel PDE-4 inhibition, TYK-2 blockage, and oral IL-23i.
  • Dr. Boni Elewski gave a talk on Nail Psoriasis or Onychomycosis? Pearls on Diagnosis and Management of Psoriatic Nail Disease and shared clues to aid the diagnosis.
  • Dr. Kenneth Gordon, IPC Councilor, and Dr. Bruce Strober, IPC Board Member, presented both sides of a debate titled: Will Non-steroidal Topical Medications Replace Topical Steroids in the Treatment of Psoriasis? Dr. Strober shared the viewpoint that non-steroidal topical medications will replace steroids, while Dr. Gordon shared details of the ongoing success of topical steroids.
  • Dr. Joel Gelfand, IPC Board Member, spoke on Mastering the Use of IL-23 Inhibitors in Psoriasis and Psoriatic Arthritis. Dr. Gelfand presented data on long-lasting efficacy, safety, and experimental dosage regimens.
  • Practical Considerations in Using IL-17 Inhibitors for Psoriasis and Psoriatic Arthritis was presented by IPC Councilor Dr. Joseph Merola. Dr. Merola reviewed the effectiveness of this drug class together with new developments.
  • Dr. Mark Lebwohl, IPC Councilor, presented Dopplegängers or Twins? What to Know About Biosimilars. Dr. Lebwohl defined biosimilars and shared their mechanisms of action.
  • Another debate on Oral versus Biologic Therapy for the Treatment of Mild to Moderate Psoriasis was presented by Dr. Kristina Callis-Duffin, IPC Councilor, and Dr Wilson Liao, IPC Councilor.

INFLAMMATORY SKIN DISEASE: THE TRANSLATIONAL REVOLUTION

  • In his talk, The Translational Revolution in Inflammatory Skin Diseases, Dr. Mark Lebwohl, IPC Councilor, reviewed the evolving field of targeted therapies in psoriasis and atopic dermatitis.
  • In the talk titled Psoriasis: A Model of Disease for Therapeutic TargetingDr. Bruce Strober, IPC Board Member, reviewed diverse scientific advances in psoriasis treatment (biologics, new oral targeted, and topical medications).

PSORIASIS: MODERN THERAPEUTIC APPROACHES

  • Update on Pipeline Therapies for Psoriasis was presented by Dr. Bruce Strober, IPC Board Member, who reviewed the newly developed drugs for psoriasis and efficacy and safety data of Bimekizumab, IL-17A/F dual inhibition, recently approved in the US.
  • Dr. Richard Langley, IPC Councilor, discussed Early Treatment of Psoriasis: A Window of Opportunity? He addressed the correlation of early treatment with early diagnosis and possible changes in long-term outcomes, such as preventing comorbidities and progression.
  • Dr. Jeffrey Marcus Cohen presented his talk Impact on Comorbidities for Biologic Selection for Psoriasis. He reviewed different considerations that prompt personalized care, such as infections, heart failure, neurological disease, and inflammatory bowel disease.
  • During her talk, Clinical Considerations in Managing Women with Psoriasis, Dr. Jennifer Soung showed data regarding the importance of a gender-sensitive approach to psoriasis.
  • Dr. Mona Shahriari discussed the Comparative Efficacy and Relative Ranking of Psoriasis Biologics with Real-World and Clinical Trial Data from drugs with different mechanisms of action (TNF alpha, IL17, IL12/23, IL23 inhibitors).
  • Dr. Joel Gelfand, IPC Board Member, presented Translating AAD/NPF Guidelines to Your Clinical Practice to Lower Cardiovascular Risk in Patients with Psoriasis. He reviewed the link between psoriasis and cardiovascular disease (CV) and the effects of systemic drugs lowering CV risks.
  • Dr. Kenneth Gordon, IPC Councilor, discussed Treating Psoriasis While Preventing Psoriatic Arthritis: What are the Early Data? He stated that while there are observational studies, results are still inconclusive, and there is a need for randomized controlled trials.

PSORIASIS AND ATOPIC DERMATITIS: ADVANCES IN COMORBIDITIES AND THERAPY

  • Dr. Kenneth Gordon, IPC Councilor, gave a talk entitled New and Emerging Biologics. He summarized the clinically relevant information regarding new treatment strategies.
  • Dr. Julia-Tatjana Maul, IPC Councilor, stated that psoriasis is a chronic systemic inflammatory disease that may result in diverse significant clinical consequences during her talk Psoriasis Comorbidities.

LATE BREAKING RESEARCH

  • Dr. Andrew Blauvelt, IPC Board Member, presented the High Induction Dosing of Risankizumab in Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from Phase 2 KNOCKOUT Study, which evaluated the number of T resident memory cells and assessed efficacy and safety.
  • Dr. Joel Gelfand, IPC Board Member, shared the Light Treatment Effectiveness (LITE) Study: A Pragmatic Trial of Home vs Office-Based Narrowband UVB Phototherapy for the Treatment of Psoriasis in the US. Dr. Gelfand shared that phototherapy is a cost-effective alternative for treatment, and the study showed that 60% of patients had a clear to almost clear response.
  • Dr. Kim Papp presented the Efficacy and Safety of ESK-001, a Highly Selective Oral TYK2 Inhibitor, in a Phase 2 Study in Adults with Moderate to Severe Plaque Psoriasis (STRIDE). Dr. Papp shared that, in general, ESK-001 was safe and well-tolerated across dose levels.
  • Dr. Laura Ferris presented A Phase 2b, Long-Term Extension, Dose-Ranging Study of Oral JNJ-77242113 for the Treatment of Moderate to Severe Plaque Psoriasis: FRONTIER 2.
  • Dr. Tadashi Teuri, IPC Councilor, shared data on the Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 16-week Results from a Phase 3, Randomized, Placebo-Controlled Trial.
  • Dr. Mark Lebwohl, IPC Councilor, discussed Bimekizumab Efficacy from Treatment Initiation Through 4 Years in Patients with Plaque Psoriasis: A Comprehensive, Long Term, Pooled Analysis from BE BRIGHT. Results from this study showed that PASI90 responses over four years remained stable (88% of patients).
  • Dr. Yuling Shi (on behalf of Dr. Jiajing Lu) presented that Guselkumab Showed Good Efficacy in Treating Generalized Pustular Psoriasis with Low Relapse Rate and Reduction in CD8+ Tissue Resident Memory T Cells.

For those seeking a more detailed understanding of these sessions, we recommend downloading the complete 2024 AAD Congress Report.

2 thoughts on “Focus on Psoriasis: A Report from the 2024 American Academy of Dermatology (AAD) Annual Meeting

  1. Ritesh roy says:

    Any oral affordable medicine discussed in the meeting

  2. Prakash D says:

    Please focus on research in Curable medication for Psoriasis

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

New IPC Guidelines on Generalized Pustular Psoriasis

Commentary: An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

Introducing our Latest IPC Councilors: Experts in Psoriasis Treatment and Research

Also Read

Generalized Pustular Psoriasis

New IPC Guidelines on Generalized Pustular Psoriasis

Learn about the new global diagnostic criteria for Generalized Pustular Psoriasis as set by the International Psoriasis Council. Discover the essential features, the importance of accurate diagnosis, and the expected global impact on patient care.

Read More
Biological agents for psoriasis

Commentary: An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

This commentary provides expert analysis on recent research findings, clinical trial results, and the promising future of therapies for individuals with moderate to severe plaque psoriasis. Uncover the latest advancements in psoriasis treatments, focusing on the significant impact of new biological agents and oral IL-23 receptor antagonists.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.